Cat. No.: HY-130603

DCZ0415

6 Cited Publications

Avis client

Based on 6 publication(s) in Google Scholar

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.81%
CAS No.: 2242470-43-3
Formule: C₂₃H₂₀N₂O₂
Masse moléculaire:356.42

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

DCZ0415 Chemical Structure

CAS No.: 2242470-43-3

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

NF-κB

Voir tous les produits spécifiques à Isoform NF-κB :

Cellular Effect

Cell Line	Type	Value	Description	References
NCI-H929	IC₅₀	6.88 μM Compound: DCZ0415	Anti-proliferative activity against human NCI-H929 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay Anti-proliferative activity against human NCI-H929 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay	[PMID: 39083980]

In Vitro

DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation^[1].
DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability in MM cells^[1].
DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death^[1].
DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells^[1].
DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells^[1].
DCZ0415 has IC₅₀s of 1.0–10 μM in CalcuSyn in MM cell lines^[1].
DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Multiple myeloma (MM) cells
Concentration:

10, 20 μM
Incubation Time:

72 hours
Result:

Showed a significant decrease in colony formation, indicating it inhibits cell proliferation.

Cell Viability Assay^[1]

Cell Line:

MM cells
Concentration:

1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time:

72 hours
Result:

Induced a significant dose-dependent decrease of viability.

Apoptosis Analysis^[1]

Cell Line:

MM cells
Concentration:

10, 20 μM
Incubation Time:

24, 48, 72 hours
Result:

Showed a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death.

Cell Cycle Analysis^[1]

Cell Line:

MM cells
Concentration:

10 and 20 μM
Incubation Time:

24 hours
Result:

Induced a significant accumulation in G0/G1 MM cells.

Western Blot Analysis^[1]

Cell Line:

MM cells
Concentration:

10 μM
Incubation Time:

48 hours
Result:

Decreased the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells.

In Vivo

DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Nude mice (6-weeks-old) with H929 775 cells^[1]
Dosage:

50 mg/kg
Administration:

Intraperitoneal injection; every day for 14 days
Result:

Significantly reduced the growth of MM cells-induced tumors.

Chemical Information

CAS No. 2242470-43-3
Appearance Solid
Masse moléculaire 356.42
Formule C₂₃H₂₀N₂O₂
Color Off-white to yellow
SMILES

O=C1N(C2=CC=C(CC3=CC=NC=C3)C=C2)C(C4C5C(C6)C6C(C=C5)C14)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All

Sort by:

Journal Impact Factor

Neoplasia

Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. [Abstract]

2024 Jan:47:100951. PMID: 38039923
ACS Omega

TRIP13 Plays an Important Role in the Sensitivity of Leukemia Cell Response to Sulforaphane Therapy. [Abstract]

2024 Jun 6;9(24):26628-26640. PMID: 38911763
Transl Oncol

AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progression. [Abstract]

2026 Jun:68:102743. PMID: 42000600
J Cancer

Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. [Abstract]

2022 Apr 11;13(7):2226-2237. PMID: 35517402
medRxiv

Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer. [Abstract]

2025 Aug 28:2025.08.25.25333715. PMID: 40909841
bioRxiv

2024 Apr 12.

Solvant et solubilité

In Vitro:

DMSO : 62.5 mg/mL (175.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8057 mL

14.0284 mL

28.0568 mL

5 mM

0.5611 mL

2.8057 mL

5.6114 mL

10 mM

0.2806 mL

1.4028 mL

2.8057 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8057 mL	14.0284 mL	28.0568 mL	70.1420 mL
	5 mM	0.5611 mL	2.8057 mL	5.6114 mL	14.0284 mL
	10 mM	0.2806 mL	1.4028 mL	2.8057 mL	7.0142 mL
	15 mM	0.1870 mL	0.9352 mL	1.8705 mL	4.6761 mL
	20 mM	0.1403 mL	0.7014 mL	1.4028 mL	3.5071 mL
	25 mM	0.1122 mL	0.5611 mL	1.1223 mL	2.8057 mL
	30 mM	0.0935 mL	0.4676 mL	0.9352 mL	2.3381 mL
	40 mM	0.0701 mL	0.3507 mL	0.7014 mL	1.7535 mL
	50 mM	0.0561 mL	0.2806 mL	0.5611 mL	1.4028 mL
	60 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1690 mL
	80 mM	0.0351 mL	0.1754 mL	0.3507 mL	0.8768 mL
	100 mM	0.0281 mL	0.1403 mL	0.2806 mL	0.7014 mL

Keywords

DCZ0415

6 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

DCZ0415

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) DCZ0415

Voir tous les produits spécifiques à Isoform NF-κB

Activité biologique

Chemical Information

Publications (6)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

DCZ0415 Related Classifications

Cat. No.: HY-130603